Alnylam’s stock continues to fall as weekly roundup highlights Q2 earnings across biopharma
read at Endpoints ↗EarningsNegative
The August 1 edition of Endpoints Weekly opens with a look at the latest biopharma earnings season.
Alnylam Therapeutics is highlighted for a continued decline in its share price, reflecting ongoing challenges for the company.
The issue also surveys Q2 results from a range of biotech firms, noting the broader earnings activity that investors are tracking.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Alnylam's slump deepens; Q2 earnings roundup; and more”
read at Endpoints ↗83 words · retrieved Aug 1
comments(0)
5-min edit window · permanent after that